These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 16537796

  • 21. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H, Tonge PJ.
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [Abstract] [Full Text] [Related]

  • 22. Synthesis of a C-glucosylated cyclopropylamide and evaluation as a glycogen phosphorylase inhibitor.
    Bertus P, Szymoniak J, Jeanneau E, Docsa T, Gergely P, Praly JP, Vidal S.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4774-8. PubMed ID: 18701279
    [Abstract] [Full Text] [Related]

  • 23. In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test.
    Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Dertinger SD, Abramsson-Zetterberg L, Krishna G, Morita T, Russo A, Asano N, Suzuki H, Ohyama W, Gibson D, In Vivo Micronucleus Assay Working Group, IWGT.
    Mutat Res; 2007 Feb 03; 627(1):10-30. PubMed ID: 17157053
    [Abstract] [Full Text] [Related]

  • 24. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 03; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 03; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 26. Effect of subchronic exposure to malathion on glycogen phosphorylase and hexokinase activities in rat liver using native PAGE.
    Rezg R, Mornagui B, El-Arbi M, Kamoun A, El-Fazaa S, Gharbi N.
    Toxicology; 2006 Jun 01; 223(1-2):9-14. PubMed ID: 16621213
    [Abstract] [Full Text] [Related]

  • 27. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
    Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K.
    Drug Metab Dispos; 2007 Jul 01; 35(7):1232-8. PubMed ID: 17392390
    [Abstract] [Full Text] [Related]

  • 28. Hypoglycemic effect of a novel dialysed fenugreek seeds extract is sustainable and is mediated, in part, by the activation of hepatic enzymes.
    Vijayakumar MV, Bhat MK.
    Phytother Res; 2008 Apr 01; 22(4):500-5. PubMed ID: 18338783
    [Abstract] [Full Text] [Related]

  • 29. Acute exercise reduces insulin resistance-induced TRB3 expression and amelioration of the hepatic production of glucose in the liver of diabetic mice.
    Lima AF, Ropelle ER, Pauli JR, Cintra DE, Frederico MJ, Pinho RA, Velloso LA, De Souza CT.
    J Cell Physiol; 2009 Oct 01; 221(1):92-7. PubMed ID: 19492410
    [Abstract] [Full Text] [Related]

  • 30. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide.
    Subramanian R, Asmawi MZ, Sadikun A.
    Acta Biochim Pol; 2008 Oct 01; 55(2):391-8. PubMed ID: 18511986
    [Abstract] [Full Text] [Related]

  • 31. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
    Chen L, Li H, Liu J, Zhang L, Liu H, Jiang H.
    Bioorg Med Chem; 2007 Nov 01; 15(21):6763-74. PubMed ID: 17719791
    [Abstract] [Full Text] [Related]

  • 32. Antioxidative enzyme and glutathione S-transferase activities in diabetic rats exposed to long-term ASA treatment.
    Lapshina EA, Sudnikovich EJ, Maksimchik JZ, Zabrodskaya SV, Zavodnik LB, Kubyshin VL, Nocun M, Kazmierczak P, Dobaczewski M, Watala C, Zavodnik IB.
    Life Sci; 2006 Oct 04; 79(19):1804-11. PubMed ID: 16815474
    [Abstract] [Full Text] [Related]

  • 33. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C.
    Diabetes; 2006 Aug 04; 55(8):2159-70. PubMed ID: 16873678
    [Abstract] [Full Text] [Related]

  • 34. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
    Masubuchi N, Makino C, Murayama N.
    Chem Res Toxicol; 2007 Mar 04; 20(3):455-64. PubMed ID: 17309281
    [Abstract] [Full Text] [Related]

  • 35. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics.
    Sinan S, Kockar F, Arslan O.
    Biochimie; 2006 May 04; 88(5):565-74. PubMed ID: 16600468
    [Abstract] [Full Text] [Related]

  • 36. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 04; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 37. Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase.
    Chen J, Liu J, Zhang L, Wu G, Hua W, Wu X, Sun H.
    Bioorg Med Chem Lett; 2006 Jun 01; 16(11):2915-9. PubMed ID: 16546381
    [Abstract] [Full Text] [Related]

  • 38. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes.
    Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I.
    Drug Metab Dispos; 2008 Jul 01; 36(7):1275-82. PubMed ID: 18388177
    [Abstract] [Full Text] [Related]

  • 39. Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity.
    Lee DS, Lee JM, Kim SU, Chang KT, Lee SH.
    Int J Mol Med; 2007 Sep 01; 20(3):379-83. PubMed ID: 17671744
    [Abstract] [Full Text] [Related]

  • 40. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice.
    Choi MS, Jung UJ, Yeo J, Kim MJ, Lee MK.
    Diabetes Metab Res Rev; 2008 Sep 01; 24(1):74-81. PubMed ID: 17932873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.